Collectively, our findings suggest that inhibition of LRRK2 kinase activity may be sufficient to exert therapeutically relevant effects in neurons and astrocytes in the context of GBA-PD models, but there are also limitations. This evidence concerns the gene LRRK2 and Parkinson disease.